Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
March 2022
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221733
EULAR recommendations can guide clinical practice and future research for improving cardiovascular risk (CVR) management in rheumatic and musculoskeletal diseases.
February 2022
Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.